Granules India facility gets 3 observations during USFDA audit
New Delhi: Drug firm Granules India has received three observations from the USFDA for its Jeedimetla, Hyderabad facility during a recent inspection.US Food and Drug Administration (USFDA) completed the inspection of company's two facilities, one located at Vizag in Andhra Pradesh and another at Jeedimetla in Telangana, Granules India said in a regulatory filing."There are no observations...
Login or Register to read the full article
New Delhi: Drug firm Granules India has received three observations from the USFDA for its Jeedimetla, Hyderabad facility during a recent inspection.
US Food and Drug Administration (USFDA) completed the inspection of company's two facilities, one located at Vizag in Andhra Pradesh and another at Jeedimetla in Telangana, Granules India said in a regulatory filing.
"There are no observations for Vizag facility and three observations for Jeedimetla facility. The company will respond to the observations in 15 business days", it added.
The Hyderabad-based firm serves customers in over 60 countries and has manufacturing footprint in India and China.
It has three facilities in Hyderabad and one in Jingmen, China. A fifth factory is under construction in Vizag through its JV company Granules OmniChem.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd